The Innovative Medicines Initiative (IMI) has now launched its 17th Call for proposals under IMI2.
Modern medicine relies more and more on knowledge acquired in molecular biology and genetics. Therefore, the research into molecular markers revolutionising the diagnosis of diseases has also become extremely timely both for academic basic research and for pharmaceutical research. In order to harmonise the efforts of discovery research and industrial pharmaceutical developments, the Molecular Biomarker Research and Service Centre of Eötvös Loránd University (ELTE Biotechnology HEICC) was established, about the goals and achievements of which, we interviewed Professor Imre Kacskovics, head of Department of Immunology of Eötvös Loránd University (ELTE).
Professor László Gránásy and his team are engaged in modelling the formation of polycrystalline materials, a research they were granted funds for early in 2018 under the “Frontline” – Excellence Programme developed by the NRDI Office. The goal, after having fully understood the crystallisation process, is to use the results in biological systems.
